Bull
$40.64
Scenario price
$60.440
-0.121 (-0.20%)At close
ScanSource, Inc. is a technology distributor converging technologies and to accelerate growth for channel sales partners across hardware, software as a service (SaaS), connectivity and cloud services. It uses multiple sales models to offer technology solutions from suppliers of specialty technologies, connectivity and cloud services. Its segments include Specialty Technology Solutions and Intelisys & Advisory. The Specialty Technology Solutions segment operates primarily in the United States and Brazil and includes specialty technology solutions distributed through a wholesale/resale sales model. This segment includes hardware, SaaS and subscription services. The Intelisys & Advisory segment operates in the United States and consists of sales and services to both channel sales partners and end users. This segment also includes Connectivity and Software-Defined Networking, Unified Communications as a Service and Contact Center as a Service, Security, Cloud/Data Center, among others.
ScanSource Inc is a good buy right now due to its strong financial performance, highlighted by a record EPS of $1.46 for Q4, which represents a 43.1% year-over-year increase. Additionally, the company's gross margin is stable at around 12%, and it has a positive outlook for free cash flow of at least $85 million for fiscal year 2027. However, investors should be cautious about the recent news of flat sales over the past two years, which indicates challenges in its market position.
Barclays
$51
2026-10-12
Barclays
2026-10-12
Price Target
$51
Raymond James
—
2024-08-15
Raymond James
2024-08-15
Price Target
—
Northcoast Research
$36
2023-12-19
Northcoast Research
2023-12-19
Price Target
$36
Raymond James
$35
2023-11-10
Raymond James
2023-11-10
Price Target
$35
Northcoast Research
—
2023-08-23
Northcoast Research
2023-08-23
Price Target
—
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Two Strong Stocks and One Underperformer

ScanSource Acquires MicroAge for $220.5 Million in Cash

ScanSource Reports Strong Q4 Growth with Record Earnings and Strategic Acquisition

ScanSource Reports Strong Q2 Growth Driven by Acquisitions and Partner Engagement

ScanSource's Strong Earnings Propel Stock Surge
ScanSource, Inc. is a technology distributor converging technologies and to accelerate growth for channel sales partners across hardware, software as a service (SaaS), connectivity and cloud services. It uses multiple sales models to offer technology solutions from suppliers of specialty technologies, connectivity and cloud services. Its segments include Specialty Technology Solutions and Intelisys & Advisory. The Specialty Technology Solutions segment operates primarily in the United States and Brazil and includes specialty technology solutions distributed through a wholesale/resale sales model. This segment includes hardware, SaaS and subscription services. The Intelisys & Advisory segment operates in the United States and consists of sales and services to both channel sales partners and end users. This segment also includes Connectivity and Software-Defined Networking, Unified Communications as a Service and Contact Center as a Service, Security, Cloud/Data Center, among others. It operates in the Technology sector (WHOLESALE-COMPUTERS & PERIPHERAL EQUIPMENT & SOFTW industry).
ScanSource Inc is a good buy right now due to its strong financial performance, highlighted by a record EPS of $1.46 for Q4, which represents a 43.1% year-over-year increase. Additionally, the company's gross margin is stable at around 12%, and it has a positive outlook for free cash flow of at least $85 million for fiscal year 2027. However, investors should be cautious about the recent news of flat sales over the past two years, which indicates challenges in its market position.
4 analysts cover SCSC: 2 rate it Buy, 2 Hold and 0 Sell. The average price target is 43.00.
No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.